Comparison of continuous versus intermittent enteral nutrition in critically ill patients (COINN): study protocol for a randomized comparative effectiveness trial

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

HRDÝ Ondřej VRBICA Kamil STRAŽEVSKÁ Eva SUK Petr SOUČKOVÁ Lenka ŠTĚPÁNOVÁ Radka SAS Igor GÁL Roman

Year of publication 2020
Type Article in Periodical
Magazine / Source Trials
MU Faculty or unit

Faculty of Medicine

Citation
Web https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04866-2
Doi http://dx.doi.org/10.1186/s13063-020-04866-2
Keywords Critical Care; Diarrhoea; Enteral nutrition; Gastric residual volume; Intensive care unit.
Attached files
Description BackgroundEnteral nutrition is part of the treatment of critically ill patients. Administration of enteral nutrition may be associated with signs of intolerance, such as high gastric residual volumes, diarrhea, and vomiting. Clinical trials regarding the effects of the mode of administration of enteral nutrition on the occurrence of these complications have yielded conflicting results. This trial aims to investigate whether the mode of administration of enteral nutrition affects the time to reach nutritional targets, intolerance, and complications.MethodsCOINN is a randomized, monocentric study for critically ill adult patients receiving enteral nutrition. Patients will be randomly assigned to two groups receiving (1) continuous or (2) intermittent administration of enteral nutrition. Enhancement of enteral nutrition will depend on signs of tolerance, mainly the gastric residual volume. The primary outcome will be the time to reach the energetic target. Secondary outcomes will be the time to reach the protein target, tolerance, complications, hospital and ICU lengths of stay, and 28-day mortality.DiscussionThis trial aims to evaluate whether the mode of application of enteral nutrition affects the time to reach nutritional targets, signs of intolerance, and complications.Trial registrationClinicalTrials.gov NCT03573453. Registered on 29 June 2018.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info